Watch: Biotech Going Up Against Big Pharma

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”

Latest

‘Mr. Supply Chain’ on Careers in an Evolving Logistics Landscape
April 22, 2021
Supply chains have been a hot topic of conversation since the COVID-19 pandemic began, as the ensuing chaos ground many of them across the world to a screeching halt. Now, however, with a new normal coming to life Read more
Getting the Most Out of Handyman Services in Facilities Management
April 22, 2021
There’s a lot to be said for specialized vendors capable of getting your most specialized, niche equipment back up and running in no time flat – but there are also repairs and maintenance challenges facilities Read more
Why You Should be Hyped About Your “Happy Accidents”
April 22, 2021
Retail is exciting, fast-moving, and filled with opportunity, yet information overload is a constant challenge. Join retail strategist, speaker, and trainer Carol Spieckerman every other Thursday as she navigates Read more